Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Short-term (8 Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes With Armodafinil Treatment (150 to 250 mg/Day) for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

NCT00228566 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00228566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00228566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Short-term (8 Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes With Armodafinil Treatment (150 to 250 mg/Day) for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
Lead sponsor
Cephalon
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2005
Completion date
July 31, 2006
Enrollment
247 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

excessive daytime sleepiness, narcolepsy, obstructive sleep apnea/hypopnea syndrome (osahs)